<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287921</url>
  </required_header>
  <id_info>
    <org_study_id>MBW-hyperinflation</org_study_id>
    <nct_id>NCT03287921</nct_id>
  </id_info>
  <brief_title>Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD</brief_title>
  <official_title>Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current guideline-based criteria defining COPD do not meet the challenges set by the complex
      pathophysiology of the disease. Hyperinflation and affection of the small airways are two
      components that are not represented in current diagnostic concepts and may relate to early
      stages of the disease. Moreover, optimal therapeutic interventions in patients with these
      distinct features remain unclear. The investigators therefore aimed to evaluate novel or not
      widely used diagnostic approaches for the detection and initiating therapeutic strategies in
      early stage COPD within the GOLD recommendations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>residual volume</measure>
    <time_frame>8 weeks</time_frame>
    <description>change in residual volume from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>D5-20</measure>
    <time_frame>8 weeks</time_frame>
    <description>change in frequency dependence of resistance from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LCI</measure>
    <time_frame>8 weeks</time_frame>
    <description>change in lung clearance index from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tpeak</measure>
    <time_frame>8 weeks</time_frame>
    <description>increase in exercise duration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IC</measure>
    <time_frame>8 weeks</time_frame>
    <description>increase in inspiratory capacity (isotime and resting) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ</measure>
    <time_frame>8 weeks</time_frame>
    <description>improvement in St. George's Respiratory Questionaire from baseline</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>mono bronchodilatation</arm_group_label>
    <description>patients with COPD and features of hyperinflation and small airway disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dual bronchodilatation</arm_group_label>
    <description>patients with COPD and features of hyperinflation and small airway disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mono bronchodilatation</intervention_name>
    <description>within indication according to current GOLD recommendation</description>
    <arm_group_label>mono bronchodilatation</arm_group_label>
    <arm_group_label>dual bronchodilatation</arm_group_label>
    <other_name>bronchodilator monotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dual bronchodilatation</intervention_name>
    <description>within indication according to current GOLD recommendation</description>
    <arm_group_label>mono bronchodilatation</arm_group_label>
    <arm_group_label>dual bronchodilatation</arm_group_label>
    <other_name>dual bronchodilator therapy</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        hospitalized patients and out-patients with known or firstly diagnosed COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  known or first diagnosis of COPD

          -  lung function testing consistent with hyperinflation or peripheral obstruction

          -  emphysema in imaging

          -  symptoms (dyspnea, cough, sputum) and risk factors (&gt;= 10 pack years)

          -  indication for bronchodilator therapy

        Exclusion Criteria:

          -  GOLD stages 3 and 4 (spirometric)

          -  indication for dual bronchodilator therapy, triple therapy or inhaled steroid

          -  contraindication for cardiopulmonary exercise testing

          -  unwilling to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Trinkmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederik Trinkmann, MD</last_name>
    <phone>+496213833879</phone>
    <email>frederik.trinkmann@umm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Trinkmann, MD</last_name>
      <phone>+496213833879</phone>
      <email>frederik.trinkmann@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2017</study_first_submitted>
  <study_first_submitted_qc>September 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Dr. Frederik Trinkmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pulmonary care</keyword>
  <keyword>COPD</keyword>
  <keyword>small airway disease</keyword>
  <keyword>hyperinflation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

